pI: 5.0022 |
Length (AA): 146 |
MW (Da): 16112 |
Paralog Number:
1
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
PDB Structures:
Ortholog group members (OG5_128555)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT5G38890 | nucleic acid-binding, OB-fold-like protein |
Arabidopsis thaliana | AT5G18470 | curculin-like (mannose-binding) lectin family protein |
Babesia bovis | BBOV_IV004430 | conserved hypothetical protein |
Brugia malayi | Bm1_53645 | 3'-5' exoribonuclease CSL4 homolog |
Candida albicans | CaO19.1026 | similar to S. cerevisiae CSL4 (YNL232W) exosome component involved mRNA degradation and nuclear RNA processing |
Candida albicans | CaO19.8628 | similar to S. cerevisiae CSL4 (YNL232W) exosome component involved mRNA degradation and nuclear RNA processing |
Caenorhabditis elegans | CELE_Y48A6B.5 | Protein EXOS-1 |
Dictyostelium discoideum | DDB_G0285377 | hypothetical protein |
Drosophila melanogaster | Dmel_CG6249 | CG6249 gene product from transcript CG6249-RA |
Echinococcus granulosus | EgrG_000727700 | exosome complex component CSL4 |
Echinococcus multilocularis | EmuJ_000727700 | exosome complex component CSL4 |
Homo sapiens | 51013 | exosome component 1 |
Loa Loa (eye worm) | LOAG_02001 | hypothetical protein |
Mus musculus | ENSMUSG00000034321 | exosome component 1 |
Oryza sativa | 4331133 | Os02g0815800 |
Plasmodium berghei | PBANKA_0617500 | exosome complex component CSL4, putative |
Plasmodium falciparum | PF3D7_0720000 | exosome complex component CSL4, putative |
Plasmodium knowlesi | PKNH_0315400 | exosome complex component CSL4, putative |
Plasmodium vivax | PVX_096320 | exosome complex component CSL4, putative |
Plasmodium yoelii | PY00332 | 3'-5' exoribonuclease csl4 homolog (ec 3.1.13.-) (cgi-108). [human, putative |
Saccharomyces cerevisiae | YNL232W | Csl4p |
Schistosoma japonicum | Sjp_0022800 | ko:K01149 exosome component 1 [EC:3.1.13.-], putative |
Schistosoma mansoni | Smp_007540 | 3'-5' exonuclease |
Toxoplasma gondii | TGME49_203610 | 3'-5' exoribonuclease csl4, putative |
Theileria parva | TP01_0308 | hypothetical protein |
Trichomonas vaginalis | TVAG_121320 | conserved hypothetical protein |
Trichomonas vaginalis | TVAG_110240 | conserved hypothetical protein |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
CELE_Y48A6B.5 | Caenorhabditis elegans | embryonic lethal | wormbase |
CELE_Y48A6B.5 | Caenorhabditis elegans | slow growth | wormbase |
YNL232W | Saccharomyces cerevisiae | inviable | yeastgenome |
PBANKA_0617500 | Plasmodium berghei | Essential | plasmo |
TGME49_203610 | Toxoplasma gondii | Essentiality uncertain | sidik |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.